The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Stellar Biotechnologies

Monday Deal Review: January 6, 2014

  Welcome to your Monday Biotech Deal Review for Janary 6, 2014! Happy New Year! Things in 2013 slowed considerably as we approached the holiday season, however January has gotten off to a good start.

Hit the break to see this week’s major biotech news, and thank you to Jennifer Ng of Norton Rose Fulbright Canada LLP for conbtributing to this week’s post.

Read more of this post

Monday Deal Review: December 16, 2013

  Welcome to your Monday Biotech Deal Review for December 16, 2013! This week saw Cangene announce thier acqusition by Emergent BioSolutions for CDN$236 million. Further, on the commercial side, Theratechnologies, Stellar Biotechnologies and NEOMED all made announcements in the collaboration space.

Hit the break to see this week’s major biotech news.

Read more of this post

Monday Deal Review: September 30, 2013

  Welcome to your Monday Biotech Deal Review for September 30, 2013! There has been a lot of activity in the M&A and finanicngs space the last week.  Hit the break for the full rundown of the weeks’s major biotech news!

Read more of this post

Monday Deal Review: September 16, 2013

 Welcome to your Monday Biotech Deal Review for September 16, 2013! The last week saw significant activity in financing. Of note is Miraculins $1,000,000 private placement, Sirona’s private placement, and Calyx’s proposal of a new private plcaement in response to the over-subscription of its previously announced offering. Finally, Stellar has raised $10 million in the initial closing of its own private placement.

In other news, Medicago is proceeding with its plan of arrangement after havign recieved court approval for the transaction.

See what else is happening in the biotech space by hitting the break!

Read more of this post

Monday Deal Review: August 26, 2013

Welcome to your Monday Biotech Deal Review for August 26, 2013! This week’s big story was the closing of Sophiris Bio’s IPO, which raised $65 million in gross proceeds.  Antibe also closed its own IPO, rasing $3 million in aggregate proceeds.  Finally, Stellar, Biologix Hair, Zecotec Photonics and Nightinggale Informatix have either closed or announced their intent to close private placements of their own.

I’d also like to take this oppurtunity to thank Jennifer Ng, an articling student with Norton Rose Fulbright Canada LLP, who will be assisting in bringing you the Monday Deal Review each week from now on. Thanks Jennifer!

Now hit the break to see the whole story on these major deals and for the rest of the past weeks’ stories!

Read more of this post

Monday Deal Review: January 21, 2013

Welcome to your Monday Biotech Deal Review for January 21, 2013!  Medicago made news last week with a $15 million loan agreement with an unnamed pharmaceutical company. The funds are being used for Medicago’s plant-based VLP vaccine pipeline. As the agreement provides for potential licensing options with that partner, we will be watching closely to see any further announcements.

YM Biosciences, as it continues with its plan of arrangement transaction with Gilead, has received the endorsement of two proxy firms who have recommended to shareholders that they vote in favour of the transaction. This will likely allow YM Biosciences to obtain the shareholder approval required by statute to be able to continue with the arrangement.

Paladin labs, meanwhile, has closed their acquisition of a controlling stake in Ativa Pharma of Mexicom, and has also in-licensed a new biologic from Apeiron Biologics. Also, last week we saw Theratechnologies conclude their recent issues with the NASDAQ exchange by voluntarily delisting. They remain on the TSX, however.

As always, click through to see more on these deals as well as the rest of last week’s major biotech activity.

Read more of this post

Monday Biotech Deal Review: April 16 2012

Welcome to your Monday Biotech Deal Review for April 16, 2012. Highlights include deals by Bioniche, Valeant and Bunge and $5 million of equity financings.  Read on to learn more.  Read more of this post

Monday Biotech “Happy Holidays” Deal Review: December 27, 2010

Welcome to your Monday Biotech “Happy Holidays” Deal Review!  For those who may have noticed, last week the Monday Biotech Deal Review took its own holiday, so this week’s digest contains biotech news spanning the past two weeks – to ensure you don’t miss a single drummer boy’s beat.  It has been a busy two weeks, with a notable $40M public offering by YM BioSciences of common shares that was announced, priced and closed, as well as an update by Angiotech with respect to its debt restructuring efforts.  There have also been some interesting strategic partnerships and licensing activity over the break.  Read on to learn more.     Read more of this post

Monday Biotech Deal Review: November 22, 2010

Welcome to your Monday Deal Review.  There was quite a bit of Canada / U.S. crossborder investment activity last week, with a $700M note offering by Valeant, IMRIS’ USD$52M public offering, and both IMRIS and Tekmira announcing their listing on the NASDAQ.   Read on to learn more, as well as the usual summaries of recent biotech activity. Read more of this post

Monday Deal Review: November 8, 2010

Welcome to your Monday Deal Review.  The Canadian biotech sector was fairly busy this week, with approximately $17M in investment money flowing into biotech companies reviewed below.  Valeant is certainly raking the leaves this fall following the Biovail merger, settling lawsuits, entering a $1.5bn securities repurchase program, and entering strategic agreements this week after ending a collaboration last week.  Read on to learn more, as well as the usual assortment of biotech news.  Read more of this post

Monday Biotech Deal Review: October 4, 2010

This week’s Monday Deal Review brings you the usual assortment of biotech wheelings and dealings from the past week, including a summary of the newly completed Valeant / Biovail merger.  Read more of this post

Monday Biotech Deal Review: May 10, 2010

Some people were on the move this week — not only did Sanofi Canada announce 70 R&D job cuts, but BioMS took on a new banker and Labopharm, CardioComm and GeneNews all get new faces. Despite the fact that it seemed half of the country’s companies and deal-makers were at BIO in Chicago this week, there was still a fair amount of positive deal activity including numerous private placements, commercial agreements and a bit of M&Eh.

Read more of this post

Monday Biotech Deal Review: April 26, 2010

This week’s deals are highlighted by a new TSX-V listed biotech, a $16 million D round, five collaborations a FedDev win for Bioniche, and updates on this month’s flurry of financings. Read more of this post

Follow

Get every new post delivered to your Inbox.

Join 130 other followers